Heart Failure with Reduced Ejection Fraction (HFrEF)

Latest Analyses in HFrEF, Diagnosis, Pa ent Selec on, and Clinical Experience

by Prateek Chopra | May 24, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure with reduced ejection fraction (HFrEF) continues to be associated with substantial morbidity and mortality despite significant advances in therapeutic options. In the era of guideline-directed medical therapy (GDMT), a growing body of evidence has highlighted the importance of accurate diagnosis, early patient identification, and timely initiation […]

Latest Analyses in HFrEF, Diagnosis, Pa ent Selec on, and Clinical Experience Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Guideline-Directed Medical and Device Therapy in Heart Failure: Insights from theESC Heart Failure III Registry in Armenia

by Prateek Chopra | May 24, 2026 | Cardiology Conferences | ESC-HF 2026 Guideline-directed medical therapy (GDMT) and device-based interventions are well established to improve outcomes in patients with heart failure (HF). However, implementation of evidence-based therapies varies considerably across healthcare systems and may be influenced by drug availability, healthcare infrastructure, and reimbursement policies. Using data from the European Society of

Guideline-Directed Medical and Device Therapy in Heart Failure: Insights from theESC Heart Failure III Registry in Armenia Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Efficacy and Safety of Sacubitril/Valsartan in the Management of Heart Failure with Reduced Ejection on Fraction on and Chronic Kidney Disease: A Systema c Review and Meta-Analysis

by Prateek Chopra | May 23, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) and advanced chronic kidney disease (CKD) have limited therapeutic options and poor prognosis. Although sacubitril/valsartan has improved outcomes in HFrEF, major trials excluded patients with CKD stage 4 or higher, leaving uncertainty regarding its efficacy and safety in this

Efficacy and Safety of Sacubitril/Valsartan in the Management of Heart Failure with Reduced Ejection on Fraction on and Chronic Kidney Disease: A Systema c Review and Meta-Analysis Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Effect of Sacubitril/Valsartan and SGLT2 Inhibitors on Echocardiographic Responseand Clinical Outcomes A er Cardiac Resynchroniza on Therapy: Insights froma Real-world Cohort

by Prateek Chopra | May 23, 2026 | Cardiology Conferences | ESC-HF 2026 Cardiac resynchronization therapy (CRT) is recommended for symptomatic heart failure (HF) patients with prolonged QRS duration and reduced left ventricular ejection fraction (LVEF), although pivotal CRT trials predated widespread use of angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose co-transporter-2 inhibitors (SGLT2i). This study evaluated whether contemporary HF therapy influences

Effect of Sacubitril/Valsartan and SGLT2 Inhibitors on Echocardiographic Responseand Clinical Outcomes A er Cardiac Resynchroniza on Therapy: Insights froma Real-world Cohort Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Predictors of Heart Failure with Improved Ejection on Frac on: A Real-World Analysis

by Prateek Chopra | May 22, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure with improved ejection fraction (HFimpEF) is increasingly recognized as a clinically meaningful phenotype in patients with heart failure with reduced ejection fraction (HFrEF). However, the factors associated with improvement in left ventricular ejection fraction (LVEF) remain incompletely understood. This study aimed to identify predictors associated with

Predictors of Heart Failure with Improved Ejection on Frac on: A Real-World Analysis Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Left Ventricular Ejection on Fraction, Ventricular Remodelling and Outcomes After Sacubitril – Valsartan in a Real-Life Cohort

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Sacubitril–valsartan (SV) has demonstrated prognostic benefits in patients with heart failure with reduced ejection fraction (HFrEF), although its long-term impact in real-world clinical practice remains unclear. This study assessed long-term outcomes associated with SV use in a real-world HFrEF cohort. The findings were presented at Heart Failure 2026,

Left Ventricular Ejection on Fraction, Ventricular Remodelling and Outcomes After Sacubitril – Valsartan in a Real-Life Cohort Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

The Prognostic Value of NT-proBNP Variability Measured During Rou ne Follow-Up in Outpatients with Heart Failure with Reduced Ejection Fraction

by Prateek Chopra | May 19, 2026 | Cardiology Conferences | ESC-HF 2026 N-terminal pro–B-type natriuretic peptide (NT-proBNP) is an established biomarker for risk stratification in Heart Failure with reduced ejection fraction (HFrEF). However, the prognostic significance of serial variability in NT-proBNP levels during routine follow-up in clinically stable patients remains unclear. This study aimed to determine whether fluctuations in NT-proBNP

The Prognostic Value of NT-proBNP Variability Measured During Rou ne Follow-Up in Outpatients with Heart Failure with Reduced Ejection Fraction Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

Vericiguat: Standard Therapy for HFrEF

by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) continued to experience substantial morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT). The prognosis after worsening heart failure (HF) events remained poor, with approximately 37% 1-year all-cause mortality/HFH rates and 19% 1-year mortality despite optimized medical and device

Vericiguat: Standard Therapy for HFrEF Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

GDMT in HFrEF: A Complete Story or a Par al Narrative?

by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 The guideline-directed medical therapy (GDMT) has transformed the prognosis of heart failure with reduced ejec on frac on (HFrEF). The introduc on of the four founda onal pillars, ARNIs or ACE inhibitors, beta-blockers, Mineralocor coid receptor antagonists, and SGLT2 inhibitors, has substan ally reduced mortality and hospitaliza on.

GDMT in HFrEF: A Complete Story or a Par al Narrative? Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

The HFrEF Medica on Toolkit for Pa ents Who Need More: From Evidence to Implementation

by Prateek Chopra | May 14, 2026 | Cardiology Conferences | ESC-HF 2026 The session highlighted that heart failure with reduced ejec on frac on (HFrEF) has entered a contemporary treatment era characterized by rapid and comprehensive implementa on of evidence-based therapies. Despite major advances with the four founda onal pillars, ACE inhibitors/ARNIs, beta-blockers, Mineralocor coid receptor antagonists, and SGLT2 inhibitors,

The HFrEF Medica on Toolkit for Pa ents Who Need More: From Evidence to Implementation Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,
Scroll to Top